As the trading day concludes, several key developments have emerged that could impact the stock market significantly. Here are the highlights for today:
- Chijet Motor Company (CJET) has approved a reverse stock split of 1-for-30 during its annual meeting, alongside an increase in authorized share capital from $50,000 to $30 million.
- iHuman Inc. (IH) reported a Q1 2024 revenue drop of 11.4% year-over-year, reaching RMB235 million, despite a record rise in monthly active users.
- Genmab (GMAB) received a positive opinion from the EMA on its epcoritamab (TEPKINLY®) for the treatment of relapsed/refractory follicular lymphoma, marking a potential first for bispecific antibody monotherapy in the EU.
- Hywin Holdings (HYW) announced updates on its strategic transformation plan, exiting wealth management to focus on technology sectors and rebranding to Santech Holdings.
- Quhuo (QH) reported a 45% year-on-year sales surge in its homestay sector during the Labor Day holiday, with a peak occupancy of 88%.
- PTC Therapeutics (PTCT) faced a negative opinion from the EMA regarding the renewal of Translarna™ marketing authorization, although its existing approval remains valid until the end of 2024.
- ARS Pharmaceuticals (SPRY) received a positive CHMP opinion for EURneffy, an adrenaline nasal spray for anaphylaxis treatment, paving the way for potential EU approval.
- NovaBay Pharmaceuticals (NBY) is promoting its Avenova line for National Dry Eye Awareness Month, offering discounts to consumers and eyecare professionals.
These developments reflect a busy day in the markets, with companies adapting to regulatory changes, market conditions, and strategic shifts aimed at boosting shareholder value. Investors should keep a close eye on these trends as they unfold.
-sm.png){kind=logo}
